Govindarajan Raghav, Shepard Katie M, Moschonas Constantine, Chen Jack J
University of Missouri (RG), Columbia, MO; American Academy of Neurology (KMS), Minneapolis, MN; Four Peaks Neurology (CM), Scottsdale, AZ; and Marshall B. Ketchum University (JJC), Fullerton, CA.
Neurol Clin Pract. 2016 Jun;6(3):281-286. doi: 10.1212/CPJ.0000000000000243.
This article is presented as a companion to the American Academy of Neurology guideline update on the use of botulinum neurotoxin (BoNT) for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Whereas the guideline update provides clarity on the efficacy of different BoNT-branded preparations for the 4 listed indications, this companion piece identifies ambiguities in the evidence for efficacy among various brand names for a given clinical indication, their dosing equivalencies, as well as different clinical indications. This article provides guidance and background information to reduce obstacles for third party payment, especially when uncertainties exist and levels of evidence are lower.
本文作为美国神经病学学会关于使用肉毒杆菌神经毒素（BoNT）治疗眼睑痉挛、颈部肌张力障碍、成人痉挛和头痛的指南更新的配套文章呈现。虽然该指南更新明确了不同品牌BoNT制剂对所列4种适应症的疗效，但这篇配套文章指出了针对特定临床适应症的不同品牌之间在疗效证据、剂量等效性以及不同临床适应症方面存在的模糊之处。本文提供指导和背景信息，以减少第三方支付的障碍，尤其是在存在不确定性且证据水平较低的情况下。
